<unk>  develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses or the skin of the face. The most common types of<unk> s occur in the lip, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. Some may experience a sore throat that does not go away. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the<unk>  or oral cavity. Given the location of these cancers, trouble breathing may also be present. The majority of<unk>  is caused by the use of alcohol or tobacco, including smokeless tobacco, with increasing cases linked to the human papillomavirus (HPV). Other risk factors include Epstein-Barr virus, betel quid, radiation exposure, certain workplace exposures. About 90% are pathologically classified as squamous cell cancers. The diagnosis is confirmed by tissue biopsy. The degree of surrounding tissue invasion and distant spread may be determined by medical imaging and blood tests. Not using tobacco or alcohol can reduce the risk for<unk> . The HPV vaccine may reduce the lifetime risk of oral cancer if taken prior to the onset of sexual activity, but confirmation will likely not be known until around 2060. This is because oropharyngeal cancer typical presents in the 4th – 6th decade of life, and this is a relatively new vaccine. While screening in the general population does not appear to be useful, screening high risk groups by examination of the throat might be useful.<unk>  often is curable if it is diagnosed early; however, outcomes are typically poor if it is diagnosed late. Treatment may include a combination of surgery, radiation therapy, chemotherapy, and targeted therapy. Previous diagnosis and treatment of one<unk>  confers higher risk of developing a second<unk>  or recurrence. Globally,<unk>  accounts for 650,000 new cases of cancer and 330,000 deaths annually on average. In 2018, it was the seventh most common cancer worldwide with 890,000 new cases documented and 450,000 dying from the disease. In the United States,<unk>  makes up 3% of all cancer cases (averaging 53,000 new diagnoses per year) and 1.5% of cancer deaths. The 2017 worldwide figure cites<unk> s as representing 5.3% of all cancers (not including non-melanoma skin cancers). Notably,<unk>  secondary to chronic alcohol or tobacco use has been steadily declining as less of the population chronically smokes tobacco. However, HPV-associated oropharyngeal cancer is rising, particularly in younger people in westernized nations, which is thought to be reflective of changes in oral sexual practices, specifically with regard to the number of oral sexual partners. This increase since the 1970s has mostly affected wealthier nations and male populations. This is due to evidence suggesting that transmission rates of HPV from women to men are higher than men to women, as women often have a higher immune response to infection. The usual age at diagnosis is between 55 and 65 years old. The average 5-year survival following diagnosis in the developed world is 42–64%.
Head and neck cancer
Laryngeal cancer
Oral cancer
Paranasal sinus and nasal cavity cancer
Oropharyngeal cancer
Hypopharyngeal cancer
Nasal polyp
Nasal glioma